UBS raised the firm’s price target on BrightSpring Health (BTSG) to $42 from $35 and keeps a Buy rating on the shares. BrightSpring’s Q3 results were positive with another beat and raise quarter, with management expressing optimism around this momentum continuing into 2026, with a particular emphasis on the growth prospects within its infusion business, the analyst tells investors in a research note.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BTSG:
- BrightSpring Health Services, Inc.: Strong Financial Performance and Growth Prospects Justify Buy Rating
- BrightSpring Health Services, Inc.: Strong Growth Prospects and Strategic Leverage Improvement Reinforce Buy Rating
- BrightSpring Health Services Reports Strong Q3 2025 Results
- BrightSpring Health Services: Strong Fundamentals and Promising 2026 Outlook Justify Buy Rating
- BrightSpring Health reports Q3 diluted EPS 26c, consensus 33c